Mark Levin is a co-founder of Third Rock Ventures and an industry leader with 40 years of experience, including more than 30 years launching and building biotechnology companies. At Third Rock, Mark focuses on the formation and development of business strategy for the firm’s portfolio companies, as well as actively identifying and evaluating new investments. Prior to becoming involved in the creation of Fulcrum, Mark played significant roles in launching and building a number of the firm’s portfolio companies, including Voyager Therapeutics, Corvia Medical (previously DC Devices), NinePoint Medical, Eleven Biotherapeutics, Foundation Medicine, Constellation Pharmaceuticals and Warp Drive Bio. Before founding Third Rock, Mark was co-founder of Mayfield Fund's life sciences effort, where he was also the founding chief executive officer of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals. Mark served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Lilly and Genentech. Mark holds an M.S. in chemical and biochemical engineering from Washington University.